Interim Results from Ongoing Phase 1/2 Clinical Trial of Lead Immuno-Oncology Candidate to be Reported in Poster Presentation
OXFORD, UK – May 29, 2024 – 91ÌÒÉ« Therapeutics, a clinical-stage biotechnology company leveraging first-of-its-kind antigen modulation therapies to address the source of immune dysfunction in oncology and autoimmunity, today announced that the first clinical data for the company’s lead immuno-oncology candidate, GRWD5769, will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The presented findings will consist of initial data from the company’s ongoing Phase 1/2 clinical trial of the first-in-class ERAP1 inhibitor in a range of solid tumour types. The 2024 ASCO Annual Meeting is being held May 31 – June 4, 2024, in Chicago, IL.
Details of the company’s presentation at the 2024 ASCO Annual Meeting are as follows:
Abstract Number: 2589
- Title: EMITT-1: Proof-of-mechanism immunopeptidome (ImPD) effects at target PK exposure, in a Phase 1 study of GRWD5769 (a first-in-class inhibitor of Endoplasmic Reticulum Aminopeptidase 1 [ERAP1]) in patients with solid malignancies
- Presenting Author: Thomas Lillie, M.D., Ph.D., Chief Medical Officer of 91ÌÒÉ« Therapeutics
- Poster Session: Development Therapeutics – Immunotherapy
- Date/Time: Saturday, June 1, 2024, 9:00 a.m. Central Time
- Location: Poster Hall – Hall A
91ÌÒÉ« has developed and is advancing a unique immune-oncology therapeutic strategy utilizing a proprietary antigen modulation strategy to reveal novel and potent cancer antigens on the surface of tumour cells. This is achieved through oral delivery of a targeted inhibitor of the endoplasmic reticulum aminopeptidases (ERAP1 or ERAP2), key proteins in the antigen presentation pathway. The targeted inhibition of ERAP is designed to elicit a de novo T cell response against tumours and to avoid T-cell exhaustion, thereby overcoming two key resistance mechanisms to current immuno-oncology therapy. The company is conducting an ongoing adaptive Phase 1/2 clinical trial of GRWD5769, which is evaluating the safety, tolerability, and efficacy of GRWD5769, including a planned combination with the PD-1 inhibitor Libtayo® (cemiplimab), in a range of solid tumour types.
The company recently reported that it is expanding the scope of the Phase 1/2 trial, allowing for the enrollment of patients with additional tumour types. Additionally, the company has also recently initiated dosing in the study’s first combination treatment cohort.
â€
